Clinical trials: Irritable Bowel Syndrome With Constipation
- Condition Irritable Bowel Syndrome With Constipation
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Constipation Predominant Irritable Bowel Syndrome
A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C
This phase 3, 12-week, randomized, double-blind, placebo-controlled, multi-center study will evaluate the safety and efficacy of tenapanor in subjects with constipation-predominant irritable bowel syndrome (IBS-C) as defined by…
- Trial name
- T3MPO-1 (NCT02621892)
- Testing
- Tenapanor
- Where
- 111 sites in United States
- Volunteers
- 606 people
- Sponsor
- Ardelyx
Irritable Bowel Syndrome
A Trial for New Treatment of Adult Participants With Irritable Bowel Syndrome
A study to evaluate the effectiveness of oral doses of Blautix in adult participants with irritable bowel syndrome (IBS).
- Trial name
- NCT03721107
- Testing
- Blautix
- Where
- 34 sites in United States, Ireland and 1 more
- Volunteers
- 366 people
- Sponsor
- 4D pharma plc
Irritable Bowel Syndrome Characterized by Constipation
A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C)
The objective of this trial is to determine the effect of linaclotide on abdominal girth in IBS-C participants with the baseline symptoms of abdominal bloating and an increased abdominal girth.
- Trial name
- NCT02837783
- Testing
- Linaclotide
- Where
- United Kingdom
- Volunteers
- 20 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Non-Constipation Irritable Bowel Syndrome
Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
To evaluate the efficacy of a 14-day course of rifaximin given 3 times a day vs. placebo in providing adequate relief of IBS symptoms.
- Trial name
- TARGET 1 (NCT00731679)
- Testing
- Rifaximin
- Where
- 96 sites in United States, Canada
- Volunteers
- 623 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome Characterized by Constipation
The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
This is a randomized, 12-week, double-blind, placebo-controlled, dose-ranging study in patients with IBS-C.
- Trial name
- CIBS (NCT01722318)
- Testing
- Plecanatide
- Where
- 99 sites in United States
- Volunteers
- 428 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C)
The goal of this clinical trial is to learn if plecanatide can improve bowel function and relieve symptoms of irritable bowel syndrome with constipation (IBS-C) in children and adolescents aged 6 to <18 years.
- Trial name
- (IBS-C) (NCT03596905)
- Testing
- Plecanatide
- Where
- 35 sites in United States
- Volunteers
- 218 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome With Constipation
A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation
The purpose of this study is to evaluate the safety and efficacy of linaclotide for the treatment of Irritable Bowel syndrome with Constipation (IBS-C), in children age 7-17 years.
- Trial name
- LIN-MD-63 (NCT02559817)
- Testing
- Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C
- Where
- 48 sites in United States, Canada
- Volunteers
- 101 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome
Long Term Safety Study of Plecanatide
Multi-center, open-label, long-term safety study
- Trial name
- IBS-C (NCT02706483)
- Testing
- Plecanatide
- Where
- 204 sites in United States
- Volunteers
- 2,272 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome
Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome
The purpose of the study is to evaluate the safety, tolerability, and effectiveness of LX1031 versus a placebo control in subjects with non-constipating irritable bowel syndrome.
- Trial name
- NCT00813098
- Testing
- LX1031 High Dose, LX1031 Low Dose
- Where
- 36 sites in United States
- Volunteers
- 155 people
- Sponsor
- Lexicon Pharmaceuticals
Irritable Bowel Syndrome With Constipation, Functional Constipation
Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C
LIN-MD-66 is a Phase 3 open-label study with 24 weeks (Functional Constipation participants) or 52 weeks (Irritable bowel syndrome with constipation participants) of linaclotide exposure that will enroll pediatric participants…
- Trial name
- NCT04166058
- Testing
- Irritable Bowel Syndrome with Constipation (IBS-C) participants (LIN-MD-63 and LIN-MD-64 completers), Functional Constipation (FC) participants (LIN-MD-62 and LIN-MD-64 completers)
- Where
- 72 sites in United States, Canada and 2 more
- Volunteers
- 381 people
- Sponsor
- AbbVie
Chronic Idiopathic Constipation
SP-304 Dose Ranging Study in Patients With Chronic Idiopathic Constipation
This is a Phase 2a, randomized, double-blind, placebo-controlled, 14-day repeat oral, dose ranging study to determine the safety, pharmacokinetics (PK) and pharmacodynamics (PD) effects of SP-304 in patients with chronic…
- Trial name
- CIC (NCT01053962)
- Testing
- SP-304 0.3 mg, SP-304 1.0 mg, SP-304 3.0 mg
- Where
- 14 sites in United States
- Volunteers
- 84 people
- Sponsor
- Bausch Health Americas, Inc.
Chronic Constipation, Irritable Bowel Syndrome With Constipation
An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00765999
- Testing
- Linaclotide
- Where
- 118 sites in United States, Canada
- Volunteers
- 1,559 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome With Constipation
Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
The objectives of this study are to evaluate the safety, efficacy, and dose response of two delayed release formulations of linaclotide (DR; DR formulation 1 is DR1; DR formulation 2 is DR2) administered orally to patients with…
- Trial name
- NCT02559206
- Testing
- Linaclotide
- Where
- 71 sites in United States
- Volunteers
- 759 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Irritable Bowel Syndrome With Constipation, Chronic Constipation
An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation
The objective of this study is to assess the long-term safety of linaclotide administered to patients with chronic constipation (CC) or irritable bowel syndrome with constipation (IBS-C).
- Trial name
- NCT00730171
- Testing
- Linaclotide
- Where
- 116 sites in United States
- Volunteers
- 1,743 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Functional Constipation, Irritable Bowel Syndrome With Constipation
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
The objective of LIN-MD-64 is to evaluate the safety and efficacy of 12 weeks of linaclotide therapy (72 μg daily) in comparison with placebo in pediatric participants, 6 to 17 years of age, who fulfill modified Rome III Criteria…
- Trial name
- NCT04026113
- Testing
- Linaclotide
- Where
- 115 sites in United States, Belgium and 12 more
- Volunteers
- 438 people
- Sponsor
- AbbVie
Irritable Bowel Syndrome, Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00399542
- Testing
- Lubiprostone
- Volunteers
- 581 people
- Sponsor
- Sucampo Pharma Americas, LLC
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation
The primary objective of this study is to assess the potential of LINZESS® (linaclotide) treatment to induce the development of anti-drug antibodies (ADAs).
- Trial name
- NCT02590432
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 828 people
- Sponsor
- Forest Laboratories
Irritable Bowel Syndrome With Constipation
Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.
- Trial name
- NCT00380250
- Testing
- Lubiprostone
- Volunteers
- 590 people
- Sponsor
- Sucampo Pharma Americas, LLC
Irritable Bowel Syndrome Characterized by Constipation
Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
This study in patients with IBS-C is a randomized, double-blind, placebo-controlled, parallel-group clinical trial with 12 weeks of study drug therapy.
- Trial name
- IBS-C (NCT02493452)
- Testing
- Plecanatide
- Where
- 191 sites in United States
- Volunteers
- 1,135 people
- Sponsor
- Bausch Health Americas, Inc.
Irritable Bowel Syndrome Characterized by Constipation
A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
To evaluate the efficacy on abdominal symptoms (abdominal bloating, abdominal discomfort, and abdominal pain) and safety of linaclotide 290 μg administered orally to patients with IBS-C.
- Trial name
- NCT03573908
- Testing
- Linaclotide
- Where
- 79 sites in United States
- Volunteers
- 614 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.